ד”ר רפי שטרייכר

ד”ר רפי שטרייכר

פסיכיאטר בכיר – יועץ

ד”ר רפי שטרייכר הוא פסיכיאטר בכיר בבית החולים הפסיכיאטרי אברבאנל, ומרצה בכיר בפקולטה לרפואה באוניברסיטת תל-אביב. בעל ניסיון עשיר בטיפול באנשים הסובלים מדיכאון, הפרעה בי-פולארית, הפרעות חרדה, הפרעות פסיכוטיות, OCD והפרעת קשב וריכוז. מתוך אמונה בחשיבותו של השילוב בין עבודה קלינית ואקדמית, רפי עוסק במחקר ובהוראה לצד עבודתו הטיפולית בבית-החולים ובקליניקה.

 

CURRICULUM VITAE

Rafael Octavio Stryjer, M.D., ID 01354972-0,

Faculty/Dept: Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hospital/Dept: Beer Yaakov-Ness Ziona  Mental Health Center, Ness Ziona, Israel.
  1. EDUCATION

1990 – 1995            Anahuac University, Mexico City, Mexico. Medicine, M.D.

1997 – 1998            Epigmenio Gonzalez, Queretaro, Mexico. Medicine; Social services.

B. FURTHER STUDIES

1994                         United States Medical License Examination, Step 1, score 85

1995                         United States Medical License Examination, Step 2, score 84

1996                         Advanced course in Cardiac Life Support, Israel

1997                         Israeli Medical License, No. 32212

1998 – 1999           Sackler Faculty of Medicine, Tel Aviv University, postgraduate studies in Neurology.

1999 – 2001           Sackler Faculty of Medicine, Tel Aviv University, postgraduate studies in Psychiatry.

2000                         Israel Defense Forces, advanced  course in Trauma Life Support

2000 – 2002           The Freudian Field Institute, Tel Aviv Clinical Section, under the auspices of the Dept. of Psychoanalysis, University of Paris- VIII, Psychoanalysis studies.

11/2002                   Israel Medical Association- Scientific Council, Board Examination in Psychiatry, passed with distinction

2003                         Psychiatrist License, No. 20287.

C. ACADEMIC AND CLINICAL  EXPERIENCE

Academic Experience

2001 – 2005            Sackler Faculty of Medicine, Tel Aviv University, American Students Program, Psychopharmacology lecturer

2002, 2004              Asaf Harofeh Medical Center, Nursing School, Psychopharmacology lecturer

2002 – 2006           Beer Yaakov-Ness Ziona Mental Health Center, clinical researcher

2003 – 2006           Beer Yaakov-Ness Ziona Mental Health Center, coordinator of academic education and preparation for board examinations for psychiatry residents

2003                         Sackler Faculty of Medicine, Tel Aviv University, preparation for the psychiatry board nursing examination.

2003                         Ben-Gurion University of the Negev, Psychiatry lecturer to psychology students

2003                   Sackler School of Medicine, Tel Aviv University, Psychiatry lectures for medical students.

2004 – 2005         Beer Yaakov-Ness Ziona Mental Health Center, Instructor and lecturer for the Step 1 Board Examination in Psychiatry.

2004 – 2007         Sackler School of Medicine, Tel Aviv University, Psychopharmacology lectures for medical students.

Since 2004          Sackler Faculty of Medicine, Tel Aviv University, American Students Program, Psychiatry Clerkship Examiner,.

2005                   Sackler Faculty of Medicine, Tel Aviv University, Neurology Continuing Education Program, Psychopharmacology lecturer.

2005 – 2012            Sackler Faculty of Medicine, Tel Aviv University, member of admission committee for candidates to the faculty.

Since 2005              Sackler Faculty of Medicine, Tel Aviv University, Medical Program. Psychopharmacology lecturer.

2007                         Sackler Faculty of Medicine, Tel Aviv University, appointed as “Lecturer”.

2009 – 2014            Shalvata Mental Health Center, Clecrkship examination.

Since 2009              Beer Yaakov-Ness Ziona Mental Health Center, Instructor and lecturer for the Step 1 Board Examination in Psychiatry.

2014                         Beer Yaakov-Ness Ziona Mental Health Center, Clerkship Program Psychopharmacology lecturer.

2014                         Sackler Faculty of Medicine, Tel Aviv University, Continuing Study Program in Psychogeriatrics, lectured on neurotransmitters and receptors in the aging brain

Since Oct. 2014                                  Established and heads Psychopharmacology research group that includes 8 members.

Clinical Experience

1996 – 1997            Asaf Harofeh Medical Centre, Medicine internship

1997 – 1998            Epigmenio Gonsalez, Mexico, social service as independent general physician in remote rural region

09/98 – 03/99        Asaf Harofeh Medical Centre, Neurology internship

1999 – 2003            Beer Yaakov-Ness Ziona Mental Health Center, Psychiatry residency

1998 – 2003            Cardiology Clinic, ergometric stress test physician

Since 1998              Israel Defense Forces, military physician

1999 – 2003            Beer Yaakov-Ness Ziona Mental Health Centre, Nes Ziona Medicine: Psychiatry residency

2002 – 2006           Beer Yaakov-Ness Ziona Mental Health Center, staff psychiatrist in acute closed unit

2006 – 2009           Beer Yaakov-Ness Ziona Mental Health Center, senior psychiatrist in ambulatory unit

2007 – 2008           Beer Yaakov-Ness Ziona Mental Health Center, Quality Control chairperson

Since 2009              Beer Yaakov-Ness Ziona Mental Health Center, senior psychiatrist in Closed Chronic Unit.

Since 2011              Beer Yaakov-Ness Ziona Mental Health Center, member of Rehabilitation Basket Committee.

Since 2013              Israel Medical Association, member of the Residents’ Accreditation Committee.

E. ACADEMIC AND PROFESIONAL AWARDS

1995                   Outstanding medical student award. Anahuac University, Mexico City, Mexico

2002                   Outstanding total score in psychiatry board examination (Shlav Bet), score >90.

2003                   Poster Award, Israel Psychiatry Association annual meeting. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L, Rozenzcwaig S, Weizman A. “Amantadine as augmentation therapy in the management of treatment –resistant depression”.

2003                   Research Team Award, Israel Psychiatry Association annual meeting. Strous RD, Shtain M, Oselka-Goren H, Lustig M, Stryjer R, Zerzion M, Baruch Y, Chelben J. “Anticipatory reactions of psychiatric inpatients to the year 2000”.

2003                   Outstanding Resident Award, Beer Yaakov-Ness Ziona Mental Health Center.

2004                   NARSAD Young Investigator Grant Award, “National alliance for research on schizophrenia and depression (NARSAD)”. “Atenolol for the prevention of clozapine-induced sympathetic hyperactivity-related side effects. A randomized, double-blind, placebo controlled study”.

F.MEMBERSHIP IN PROFESSIONAL SOCIETIES

1999-                 Israel Medical Association

2000-2001        Israel Neurology Association

2003-2004        European College of Neuropsychopharmacology.

2003-2004        Association of Clinical Research Professionals (ACRP), Membership ID: 152417

LIST OF PUBLICATIONS

B.1. ORIGINAL ARTICLES

  1. Strous RD, Shtain M, Oselka-Goren H, Lustig M, Stryjer R, Zerzion M, Baruch Y, Chelben J.

    Anticipatory reactions of psychiatric inpatients to the year 2000. 

    J Nerv Ment Dis. 2000; 188:786-8.

  2. Stryjer R, Strous RD, Bar F, Werber E, Shaked G, Buhiri Y, Kotler M, Weizman A, Rabey JM. 

    Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. 

    Clin Neuropharmacol. 2003;60:133-41.

  3. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A.

    Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. 

    Arch Gen Psychiatry. 2003;60:133-41.

  4. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L, Rozenzcwaig S, Weizman A. 

    Amantadine as augmentation therapy in the management of treatment –resistant depression. 

    Int Clin Psychopharmacol. 2003; 18:93-6.

5.      Strous RD, Stryjer R, Keret N, Bergin M, Kotler M. 

Reactions of psychiatric and medical inpatients to terror and security instability in Israel .

J Nerv Ment Dis. 2003;191:126-9.

  1. Styrjer R, Strous RD, Bar F, Poyurovsky M, Weizman A, Kotler M. 

    Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone.

    Clin Neuropharmacol. 2003; 26:137-41.

  2. Stopkova P, Saito T, Papolos DF, Stryjer R, Strous RD, Lachman MH. 

    Polymorphism screening of PIP5K2A: A candidate gene for 10p-linked psychiatric disorders. 

    Am J Med Genet .2003:15;123B(1):50-8.

  3. Pollak L, Klein C, Stryjer R , Kossych V, Rabey 

    Anxiety in the first attack of vertigo.

    Otolaryngol Head Neck Surg. 2003; 128(6):829-34.

  4. Pollak L, Klein C, Stryjer R, Kushnir M, Teitler J. 

    Phobic postural vertigo: A new proposed entity. 

    J Isr Med 2003;10:720-723.

  5. Shiloh R, Bodinger L, Katz N, Sigler M, Stryjer R, Hermesh H, Munitz H, Weizman A. 

    Lower corneal temperature in neuroleptic-treated vs. drug-free schizophrenia patients. 

    Neuropsychobiology. 2003;48(1):1-4.

  6. Stryjer R, Strous RD, Bar F, Shaked G, Shiloh R, Rozencweig S, Grupper D, Buchman N, Kotler M, Rabey JM, Weizman A. 

    Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. 

    Human psychopharmacol Clinical and Experimental. 2004;19(5):343-346.

  7. Reznik I, Yavin I, Stryjer R , Spivak B, Gonen N, Strous RD , Weizman A, Mester R, Kotler M. 

    Clozapine in the treatment of obsessive-compulsive symptoms in chizophrenia: A case series study. 

    Pharmachopsychiatry.2004; 37(2):52-6

  8. Nahshoni E, Manor N, Bar F, Stryjer R, Zalsman G, Weizman A.

    Alterations in QT dispersion in medicated schizophrenia patients following electroconvulsive therapy. 

    European Neuropsychopharmacol. 2004; 14(2):121-5

  9. Strous RD, Strjyer R, Ofir D, Weiss M, Bar F, Baruch Y, Kotler M. 

    DSMIV self-evaluation by psychiatrists.

    Israel J Psychiatry Relat Sci . 2004;41(3):197-207.

  10. Stryjer R, Klein C, Treves T, Prohorof T, Rabey JM. 

    The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson’s disease patients. 

    Acta Neurologica Scand. 2005; 111(2):

  11. Shiloh R, Munitz H, Portuguese S, Gross-Isseroff R, Sigler M, Bodinger L, Katz N, Stryjer R, 

    Hermesh H, Weizman A. Corneal temperature in schizophrenia patients 

    International Journal of Neuropsychopharmacology. 2005;1:1-11.

  12. Schwartz K, Iancu I, Stryjer R, Chelben J, Kotler M, Weizman A, Rehavi M. 

    Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients 

    Eur Neuropsychopharmacology. 2005; 15(5):557-61.

  13. Pollak L, Stryjer R, Kushnir M, Flechter S.

    Approach to bilateral benign paroxysmal positioning vertigo 

    Am J Otolaryngol. 2006; 27(2):91-5.

  14. Pollak L, Kushnir M, Stryjer R. 

    Diagnostic value of vestibular evoked myogenic potentials in cerebellar and lower-brainstem strokes. 

    Neurophysiol Clin. 2006;36(4):227-33.

  15. Strous RD, Stryjer R, Maayan R, Gal G, Viglin D, Katz N, Eisner D, Weizman 

    Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. 

    Psychoneuroendocrinology. 2007; 32(2): 96-105.

  16. Shiloh R, Munitz  H, Stryjer R, Weizman 

    A significant correlation between ward temperature and the severity of symptoms in schizophrenia   Inpatients-A longitudinal study. 

    Eur Neuropsychopharmacol;2007; 17(6-7): 478-82

  17. Poyurovsky M, Faragian S, Pashinian A, Levi A, Viosburd A, Stryjer R, Weizman R, Fuchs C, Weizman A. 

    Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder. 

    J Neuropsychiatry Clin Neurosci. 2007 Spring;19(2):145-50

  18. Shiloh R, Kushnir T, Gilat Y, Gross-Isseroff R, Hermesh H, Munitz H, Stryjer R, Weizman A, Manor D. 

    In vivo occipital-frontal temperature-gradient in schizophrenia patients and its possible association with psychopathology: a magnetic resonance spectroscopy study. 

    Eur Neuropsychopharmacol. 2008;18:557-64. (IF 4.046; cit. 2; R 28/259)

  19. Stryjer R, Spivak B, Strous RD, Shiloh R, Harary E, Polak L, Birgen M, Kotler M, Weizman A. 

    Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. 

    Clin Neuropharmacol. 2009;32:82-4. (IF 2.166; cit. 12; R 163/259)

  20. Avital A, Gross-Isseroff R, Stryjer R, Hermesh H, Weizman A, Shiloh R. 

    Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. 

    Eur Neuropsychopharmacol. 2009;19:476-82. (IF 4.046; cit. 6; R 28/259).

  21. Shiloh R, Schapir L, Bar-Ziv D, Stryjer R, Konas S, Louis R, Hermesh H, Munitz H, Weizman A, Valevski A. 

    Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. 

    Eur Neuropsychopharmacol. 2009;19:654-8. (IF 4.046; cit. 3; R 28/259).

  22. Shiloh R, Weizman A, Stryjer R, Kahan N, Waitman DA. 

    Altered thermoregulation in ambulatory schizophrenia patients: a naturalistic study. 

    World J Biol Psychiatry. 2009;10:163-70. (IF 2.385; cit. 1; R 30/135).

  23. Stryjer R, Timinsky I, Reznik I, Weizman A, Spivak B. 

    Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. 

    Clin Neuropharmacol. 2009;32:290-2. (IF 2.166; cit. 7; R 163/259).

  24. Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B. 

    Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. 

    Clin Neuropharmacol. 2010;33:219-22. (IF 2.166; cit. 10; R 163/259).

  25. Rosenberg O, Zangen A, Stryjer R, Kotler M, Dannon PN. 

    Response to deep TMS in depressive patients with previous electroconvulsive treatment. 

    Brain Stimul. 2010;3:211-7. (IF 3.755; cit. 14; R 51/251).

  26. Stryjer R, Spivak B, Shiloh R, Polak L, Weizman A, Rabey JM. Prevalence of Dementia in an Elderly illiterate Native Mexican Population of indigenous Origin. J Public Health Epidemiology. 2011;3 pp.556-559. (No IF)
  27. Pollak L, Segal P, Stryjer R, Stern HG. Beliefs and emotional reactions in patients with benign paroxysmal positional vertigo: a longitudinal study. Am J Otolaryng. 2012;33:221-5. (IF 1.23; cit. 2; R 21/44).

  28. Stryjer R, Ophir D, Bar F, Spivak B, Weizman A, Strous RD. 

    Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. 

    Clin Neuropharmacol. 2012;35:161-4. (IF 2.166; cit. 4; R 163/259).

  29. Stryjer R, Dambinsky Y, Timinsky I, Green T, Kotler M, Weizman A, Spivak B. 

    Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. 

    Int Clin Psychopharm. 2012;28:96-8. (IF 2.918; cit. 2; R 95/259).

  30. Stryjer R, Budnik D, Ebert T, Green T, Polak L, Weizman S, Spivak B.

    Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.

    Clin Neuropharmacol (IF 1.836; cit. 1; R 160/256) 2014;37:79-81.

  31. Pollak L, Stryjer R. 

    Fatigue during an episode of benign paroxysmal positional vertigo. 

    Eur Arch Otorhinolaryngol. (IF 1.608; cit. 0; R 13/44) 2014 Apr 12. [Epub ahead of print]

B.2. CASE REPORTS

  1. Stryjer R, Strous RD, Bar F, Ulman AM, Rabey JM. 

    Segmental dystonia as the sole manifestation of carbamazepine toxicity. 

    Gen Hosp Psychiatry. 2002;24:114-5.

  2. Stryjer R, Strous RD, Baruch Y, Rabey JM. 

    Donepezil management of schizophrenia with associated dementia. 

    J Clin Psychopharmacolol. 2002:22;226-9.

  3. Strous RD, Stryjer R, Zerzion M, Weiss M, Bar F. 

    Accent echoing: a newly described imitation phenomena of psychosis? 

    Isr Med Assoc J. 2003;5:61-2.

  4. Stryjer R, Grupper D, Strous RD, Poyurovsky M, Weizman A. 

    Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient. 

    European Psychiatr . 2004;19(4):237-8

C. Chapter in book

  1. Rabey JM, Stryjer R. 

    The effect of acute loading with selegiline and selegiline and levodopa on blood pressure and plasma norepinephrine levels in chronic Parkinsonian patients. 

    In “Catecholamine Research, from molecular insights to clinical medicine”, Nagtsu T, Nabeshima T, McCarty R, Oldstein DS (eds). Kluwer Academic/Plenum Publishers, pp483-486, 2002.

  2. Stryjer R, Strous RD, Shiloh R, Poyurovsky M, Weizman A. 

    5HT2A antagonists for the management of neuroleptic induced acute akathisia. 

    In: “Focus on Serotonin Uptake Inhibitors Research”. Shirley AC (ed.). Nova Science Publishers, Inc., New-York, 2005.

  3. ITEMS IN ENCYCLOPEDIAS

“Obsessive compulsive disorder” and “Paranoia” 600 words each item. 

Medical Encyclopedia edited in Israel.

F. BOOKS EDITED

Shiloh R, Stryjer R, Weizman A, Nutt D. 

Atlas of Psychiatric Pharmacotherapy, Second Edition Taylor & Francis Books Ltd. 2005

G. OTHER PUBLICATIONS

Stryjer R. 

Case  Presentation. 

MACHBAROT FREUDIANIOT. Notebook # 11, pp. 82-83, January 2002

צרו קשר, ניפגש, נבנה ביחד תכנית טיפולית מותאמת ומדויקת

לחצו ליצירת קשר
דילוג לתוכן